Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Zimmer Biomet Holdings (NYSE:ZBH) but lowers the price target from $155 to $145.
August 08, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Zimmer Biomet Holdings but lowers the price target from $155 to $145.
The Outperform rating suggests continued confidence in Zimmer Biomet Holdings' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100